GU CONNECT powered by COR2ED

Recap from #ESMO25: Prof. Viktor Grünwald discusses emerging data in advanced renal cell carcinoma and potential implications for clinical practice. Watch the video covering LenCabo, KEYMAKER-U03, CLEAR & [68 Ga]Ga-DPI-4452 (CAIX) imaging here : cor2ed.com/n-connect/prog… #MedEd #GUOncology This programme is financially supported by an independent educational grant from Eisai Europe Limited. Eisai has financially contributed towards this material as a sponsor and has had no influence in its organisation or creation.

Revisiting #RCC data from #ESMO25 Back in October, Prof. @ViktorGruenwald shared his picks of the key data to come out of the congress How did Prof. Grünwald predict that those data would go on to impact clinical practice? 📺 Watch the video to find out Download the slides & see more updates from ESMO: cor2ed.com/n-connect/prog… ~ Endorsed by @KidneyCancer Supported by an independent educational grant from Eisai Europe Limited. Eisai has financially contributed towards this material as a sponsor and has had no influence in its organisation or creation.

>> Reviewing #RCC data from #ESMO25 📺 Prof. @ViktorGruenwald joined us at ESMO in October to share his perspective on the latest renal cell carcinoma data presented at the congress View Prof. Grünwald’s slides & see more updates from ESMO: cor2ed.com/n-connect/prog… 🤝 Endorsed by @KidneyCancer This RCC update is supported by an independent educational grant from Eisai Europe Limited. Eisai has financially contributed towards this material as a sponsor and has had no influence in its organisation or creation. #MedEd

Explore shared decision-making for prostate cancer pts & early Tx intensification w/ PARPi + ARPI combi in mCRPC 📺 Part 2 of the 2-part highlights video in this post Check out our previous post to watch part 1! #MedEd programme from Uro-Oncologist Prof. Gunhild von Amsberg >> Engaging pt case video >> Discover the SHARE Communication Framework ~ Endorsed by Urobel & @ZEROCancer ~ Supported by an Independent Educational Grant from AstraZeneca #MedEd #PCSM

Explore shared decision-making for prostate cancer pts & early Tx intensification w/ PARPi + ARPI combi in mCRPC 📺 Part 1 of the 2-part highlights video in this post Check out our next post to watch part 2! #MedEd programme from Uro-Oncologist Prof. Gunhild von Amsberg >> Engaging pt case video >> Discover the SHARE Communication Framework ~ Endorsed by Urobel & @ZEROCancer ~ Supported by an Independent Educational Grant from AstraZeneca #MedEd #PCSM

Do you treat pts w/ mCRPC and know when to consider early treatment intensification? 📺 Patient case video and ‘SHARE’ communication framework for you to use in your clinical practice >> From Uro-Oncologist Prof. Gunhild von Amsberg PART 2 OF THE HIGHLIGHTS VIDEO IN THIS POST! Check out Part 1 in our previous post 👀 ~ Endorsed by Urobel & @ZEROCancer ~ Supported by an Independent Educational Grant from AstraZeneca #MedEd #PCSM

Do you treat pts w/ mCRPC and know when to consider early treatment intensification? 📺 Patient case video and ‘SHARE’ communication framework for you to use in your clinical practice >> From Uro-Oncologist Prof. Gunhild von Amsberg PART 1 OF THE HIGHLIGHTS VIDEO IN THIS POST! Check out Part 2 in our next post 👀 ~ Endorsed by Urobel & @ZEROCancer ~ Supported by an Independent Educational Grant from AstraZeneca #MedEd #PCSM

When should early treatment intensification w/ PARPi + ARPI combination be considered for mCRPC patients? 📺 Find out in this patient case video >> You’ll also discover the SHARE Communication Framework to use with your pts in clinical practice SHARE is made up of 5 key elements: S – Success criteria & aim of treatment H – How the treatments work A – Advantages/disadvantages of each Tx option R – Risks & effective management of side effects E – Expectations for Tx success Part 1 of the highlights video in this post ~ Endorsed by Urobel & @ZEROCancer Supported by an Independent Educational Grant from AstraZeneca

When should early treatment intensification w/ PARPi + ARPI combination be considered for mCRPC patients? 📺 Find out in this patient case video >> You’ll also discover the SHARE Communication Framework to use with your pts in clinical practice SHARE is made up of 5 key elements: S – Success criteria & aim of treatment H – How the treatments work A – Advantages/disadvantages of each Tx option R – Risks & effective management of side effects E – Expectations for Tx success Part 1 of the highlights video in this post ~ Endorsed by Urobel & @ZEROCancer Supported by an Independent Educational Grant from AstraZeneca

Prof. Viktor Grünwald shares key insights from ESMO 2025 on emerging data in advanced renal cell carcinoma. Highlights include evolving first- and later-line strategies, triplet regimens, and tumour-specific imaging in clear cell RCC. Watch the full video update on YouTube here: youtube.com/watch?v=KTVQvY… #RCC #RenalOncology #MedEd Supported by an independent educational grant from Eisai Europe Limited.

#RCC highlights from #ESMO25 Prof. @ViktorGruenwald joined us at ESMO to share his perspective on the latest RCC data presented at the congress 📺 Watch his short video View the slides for more detailed insights: cor2ed.com/n-connect/prog… 🤝 Endorsed by @KidneyCancer This RCC update is supported by an independent educational grant from Eisai Europe Limited. Eisai has financially contributed towards this material as a sponsor and has had no influence in its organisation or creation. #MedEd

When should early treatment intensification w/ PARPi + ARPI combination be considered for mCRPC patients? 📺 Find out in this patient case video >> You’ll also discover the SHARE Communication Framework to use with your pts in clinical practice SHARE is made up of 5 key elements: S – Success criteria & aim of treatment H – How the treatments work A – Advantages/disadvantages of each Tx option R – Risks & effective management of side effects E – Expectations for Tx success ✅ Part 2 of the highlights video in this post If you’ve not yet seen Part 1, find it in our previous post! ~ Endorsed by Urobel & @ZEROCancer ~ Supported by an Independent Educational Grant from AstraZeneca #MedEd #PCSM

When should early treatment intensification w/ PARPi + ARPI combination be considered for mCRPC patients? 📺 Find out in this patient case video >> You’ll also discover the SHARE Communication Framework to use with your pts in clinical practice SHARE is made up of 5 key elements: S – Success criteria & aim of treatment H – How the treatments work A – Advantages/disadvantages of each Tx option R – Risks & effective management of side effects E – Expectations for Tx success ✅ Part 1 of the highlights video in this post Check out Part 2 in our next post! ~ Endorsed by Urobel & @ZEROCancer ~ Supported by an Independent Educational Grant from AstraZeneca #MedEd #PCSM

Prof. Viktor Grünwald (@ViktorGruenwald) joined us at #ESMO in October to report on advanced renal cell carcinoma data from the LenCabo, KEYMAKER-U03, and CLEAR studies He also reviews the use of [68 Ga]Ga-DPI-4452 (CAIX) PET/CT for staging of disease. 📺 Watch the video View the slides & see more updates from ESMO: cor2ed.com/n-connect/prog… Endorsed by @KidneyCancer Supported by an independent educational grant from Eisai Europe Limited. Eisai has financially contributed towards this material as a sponsor and has had no influence in its organisation or creation. #MedEd #RCC

📣 New! patient case video + shared decision-making tool for pts w/ mCRPC 📺 Discover the SHARE Communication Framework to use with your patients in this patient case video Video highlights PART 2 in this post (see part 1 in our previous post!) ~ Endorsed by Urobel & @ZEROCancer ~ Supported by an Independent Educational Grant from AstraZeneca #MedEd #PCSM

📣 New! patient case video + shared decision-making tool for pts w/ mCRPC 📺 Discover the SHARE Communication Framework to use with your patients in this patient case video Video highlights PART 1 in this post (see part 2 in our next post!) ~ Endorsed by Urobel & @ZEROCancer ~ Supported by an Independent Educational Grant from AstraZeneca #MedEd #PCSM

We are proud to share that more than 50,000 HCPs around the world follow @COR2EDMedEd's programmes to stay up to date with the latest science, and provide their patients with the best possible care 🎉 ~ GU CONNECT is an initiative of COR2ED ~ 👏 Over 25k HCPs subscribe to the COR2ED YouTube channel to see educational videos as soon as they're released 👏 More than 25k followers stay up to date with #MedEd on the COR2ED social media channels on X, LinkedIn, Instagram, and BlueSky Are you part of our community yet? 🎓 Follow us for engaging videos, podcasts, publications, micro learnings, and more! Our programmes are developed by renowned medical experts and endorsed by Medical Societies & Patient Advocacy Groups ✅ Come and follow us on YouTube! @cor2edtheheartofmedicaledu700" target="_blank" rel="nofollow noopener">youtube.com/@cor2edthehear… #medicaleducation #MedTwitter #OncTwitter

Did you catch the new #RCC data presented at #ESMO25 in October? 📺 Watch the video for Prof. @ViktorGruenwald’s highlights from the congress He reviews data from the LenCabo, KEYMAKER-U03, and CLEAR studies & the use of [68 Ga]Ga-DPI-4452 (CAIX) PET/CT for staging of disease View the accompanying slides & see more updates from ESMO >> cor2ed.com/n-connect/prog… Endorsed by @KidneyCancer Supported by an independent educational grant from Eisai Europe Limited. Eisai has financially contributed towards this material as a sponsor and has had no influence in its organisation or creation. #MedEd

Certain PARPi and ARPI combination therapies are effective, even in molecularly unselected patients Explore early treatment intensification w/ PARPi + ARPI combination, inc: - Where these treatments fit into the treatment pathway and - The advantages/disadvantages of different Tx options 📺 PART 2 of the 2-part highlights video in this post (catch up on Part 1 in our previous post!) Supported by an Independent Educational Grant from AstraZeneca #MedEd #PCSM #OncTwitter

Certain PARPi and ARPI combination therapies are effective, even in molecularly unselected patients - Where do these treatments fit into the treatment pathway? - What are the advantages/disadvantages of different Tx options? Explore early treatment intensification w/ PARPi + ARPI combination 🔍 📺 PART 1 of the 2-part highlights video in this post (watch part 2 in our next post!) Supported by an Independent Educational Grant from AstraZeneca #MedEd #PCSM #OncTwitter